Diabetes, Vol 45, Issue 12 1694-1700, Copyright © 1996 by American Diabetes Association

ARTICLES

Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats

M Kochakian, BN Manjula and JJ Egan
Department of Biochemistry, Alteon, Inc., Ramsey, New Jersey, USA.

Solubility of tail tendon collagen from normal, streptozotocin-induced diabetic Lewis rats, and diabetic animals treated with aminoguanidine and two novel advanced glycosylation end products (AGE)-formation inhibitors was investigated by limited pepsin digestion under acidic conditions. Assays were conducted using tail tendon collagen from Lewis rats obtained from two different vendors, Harlan and Charles River Laboratories. Collagen solubility was assessed by following the kinetics of pepsin digestion. The data revealed that the rate of digestion for diabetic animals is markedly slow relative to that of normals. More strikingly, the kinetics of the diabetic animals showed the feature of a lag in digestion regardless of the animal source. Experiments designed to optimize the difference in solubility between normal and diabetic animals demonstrated that Charles River animals exhibit a greater window of solubility than the Harlan animals. More importantly, a pronounced effect of aminoguanidine, an AGE-formation inhibitor, was observed in Charles River animals, but not in the Harlan animals, presumably because of the larger window of solubility between the normal and the diabetic animals in the former. These data indicated that the Charles River Lewis rats are an animal model that demonstrates greater efficacy in this assay. Analysis of in vivo screens designed to test efficacy of aminoguanidine and two novel AGE-formation inhibitors, ALT 462 and ALT 486, demonstrated that monitoring an in vivo dose response is highly dependent on the enzyme concentration as well as the time of digestion, and that 1.5 h of digestion and 10 microg/ml pepsin (5 pg pepsin/mg collagen) appeared optimal. Under these conditions, a 29% normalization of solubility was observed with aminoguanidine at 100 mg/kg body wt, whereas a similar normalization was observed at 10 mg/kg body wt for both ALT 462 and ALT 486. Thus, on a molar basis, ALT 462 and ALT 486 are at least 20 times more potent than aminoguanidine. This is the first demonstration of dose-dependent efficacy for AGE-formation inhibitors in animal models, and as such, this assay provides a method with which to assess the in vivo efficacy of other such inhibitors.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. R. Sell, K. M. Biemel, O. Reihl, M. O. Lederer, C. M. Strauch, and V. M. Monnier Glucosepane Is a Major Protein Cross-link of the Senescent Human Extracellular Matrix: RELATIONSHIP WITH DIABETES J. Biol. Chem., April 1, 2005; 280(13): 12310 - 12315. [Abstract] [Full Text] [PDF]

				J. Liu, M. R. Masurekar, D. E. Vatner, G. N. Jyothirmayi, T. J. Regan, S. F. Vatner, L. G. Meggs, and A. Malhotra Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2587 - H2591. [Abstract] [Full Text] [PDF]

				M. Peppa, H. Brem, P. Ehrlich, J.-G. Zhang, W. Cai, Z. Li, A. Croitoru, S. Thung, and H. Vlassara Adverse Effects of Dietary Glycotoxins on Wound Healing in Genetically Diabetic Mice Diabetes, November 1, 2003; 52(11): 2805 - 2813. [Abstract] [Full Text] [PDF]

				R. Candido, J. M. Forbes, M. C. Thomas, V. Thallas, R. G. Dean, W. C. Burns, C. Tikellis, R. H. Ritchie, S. M. Twigg, M. E. Cooper, et al. A Breaker of Advanced Glycation End Products Attenuates Diabetes-Induced Myocardial Structural Changes Circ. Res., April 18, 2003; 92(7): 785 - 792. [Abstract] [Full Text] [PDF]

				D. R. Sell, J. F. Nelson, and V. M. Monnier Effect of Chronic Aminoguanidine Treatment on Age-Related Glycation, Glycoxidation, and Collagen Cross-linking in the Fischer 344 Rat J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2001; 56(9): B405 - 411. [Abstract] [Full Text] [PDF]

				T. S. Kern and R. L. Engerman Pharmacological Inhibition of Diabetic Retinopathy: Aminoguanidine and Aspirin Diabetes, July 1, 2001; 50(7): 1636 - 1642. [Abstract] [Full Text] [PDF]

				T. S. Kern, J. Tang, M. Mizutani, R. A. Kowluru, R. H. Nagaraj, G. Romeo, F. Podesta, and M. Lorenzi Response of Capillary Cell Death to Aminoguanidine Predicts the Development of Retinopathy: Comparison of Diabetes and Galactosemia Invest. Ophthalmol. Vis. Sci., November 1, 2000; 41(12): 3972 - 3978. [Abstract] [Full Text]

				C. M. Hogaboam, C. S. Gallinat, C. Bone-Larson, S. W. Chensue, N. W. Lukacs, R. M. Strieter, and S. L. Kunkel Collagen Deposition in a Non-Fibrotic Lung Granuloma Model after Nitric Oxide Inhibition Am. J. Pathol., December 1, 1998; 153(6): 1861 - 1872. [Abstract] [Full Text] [PDF]

				B. H. R. Wolffenbuttel, C. M. Boulanger, F. R. L. Crijns, M. S. P. Huijberts, P. Poitevin, G. N. M. Swennen, S. Vasan, J. J. Egan, P. Ulrich, A. Cerami, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes PNAS, April 14, 1998; 95(8): 4630 - 4634. [Abstract] [Full Text] [PDF]